Macquarie Group Ltd. raised its holdings in CryoLife, Inc. (NYSE:CRY) by 16.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,609,284 shares of the medical equipment provider’s stock after purchasing an additional 221,574 shares during the quarter. Macquarie Group Ltd. owned 4.81% of CryoLife worth $36,531,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Royce & Associates LP raised its position in CryoLife by 10.0% in the second quarter. Royce & Associates LP now owns 435,200 shares of the medical equipment provider’s stock valued at $8,682,000 after purchasing an additional 39,500 shares during the period. William Blair Investment Management LLC acquired a new stake in shares of CryoLife in the second quarter valued at $4,517,000. Marshall Wace North America L.P. grew its stake in shares of CryoLife by 118.4% in the second quarter. Marshall Wace North America L.P. now owns 133,021 shares of the medical equipment provider’s stock valued at $2,660,000 after buying an additional 72,114 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of CryoLife by 2.9% in the first quarter. Vanguard Group Inc. now owns 1,556,106 shares of the medical equipment provider’s stock valued at $25,909,000 after buying an additional 43,212 shares in the last quarter. Finally, Thomson Horstmann & Bryant Inc. acquired a new stake in shares of CryoLife in the second quarter valued at $1,873,000. Institutional investors own 70.26% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/cryolife-inc-cry-shares-bought-by-macquarie-group-ltd/1721791.html.

In related news, CFO David Ashley Lee sold 33,190 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total transaction of $630,610.00. Following the completion of the transaction, the chief financial officer now directly owns 324,339 shares of the company’s stock, valued at approximately $6,162,441. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James Benson sold 2,000 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $22.80, for a total value of $45,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 229,240 shares of company stock valued at $4,888,065 over the last three months. 6.00% of the stock is currently owned by insiders.

CryoLife, Inc. (NYSE CRY) opened at $19.55 on Thursday. CryoLife, Inc. has a one year low of $14.02 and a one year high of $24.00. The company has a market capitalization of $665.80, a price-to-earnings ratio of 48.54 and a beta of 0.82. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29.

CryoLife (NYSE:CRY) last released its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.08. CryoLife had a return on equity of 6.43% and a net margin of 5.28%. The firm had revenue of $44.00 million during the quarter, compared to analysts’ expectations of $44.60 million. During the same period in the previous year, the firm posted $0.13 EPS. CryoLife’s revenue for the quarter was down 2.9% on a year-over-year basis. analysts anticipate that CryoLife, Inc. will post 0.28 earnings per share for the current fiscal year.

CRY has been the subject of a number of research reports. BidaskClub cut CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research cut CryoLife from a “buy” rating to a “sell” rating in a research note on Wednesday, August 2nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $25.00 price objective on shares of CryoLife in a research note on Monday, October 9th. Lake Street Capital lifted their price objective on CryoLife to $26.00 and gave the company a “buy” rating in a research note on Wednesday, October 11th. Finally, TheStreet cut CryoLife from a “b” rating to a “c+” rating in a research note on Monday, October 30th. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $23.63.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife, Inc. (NYSE:CRY).

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.